WHO ICTRP trial

A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety…

PER-144-09 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting

Key facts

Trial ID PER-144-09
Public title A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to Severe Rheumatoid Arthritis
Scientific title A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to…
Primary sponsor F. HOFFMANN-LA ROCHE LTD.,
Registry Registro Peruano de Ensayos Clínicos (REPEC)
Recruitment status Not Recruiting
Study type Interventional
Phase III
Countries Germany;Denmark;Spain;Finland;France;Greece;Ireland;Italy;Portugal;United Kindgdom;Sweden;Hungaria;Peru
Conditions -M05 ;M05
Interventions Group name:Group 1 Type of group;1 N° of participants:282 Intervention(s) description:Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks. Group name:Goup 4 Type of group;2 N° of…
Registration date Sep 2, 2010
Target size 24
Secondary IDs NCT01007435;EUCTR2009-012759-12-GB
Registry page ins.gob.pe

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations